Abstract
Regulatory T cells (Tregs) are a specialized subset of T lymphocytes that function as suppressive immune cells and inhibit various elements of immune response in vitro and in vivo. While there are constraints on the number or function of Tregs which can be exploited to evoke an effective anti-tumor response, sufficient expansion of Tregs is essential for successful organ transplantation and for promoting tolerance of self and foreign antigens. The immune-suppressive property of Tregs equips this T lymphocyte subpopulation with a pivotal role in the establishment and maintenance of maternal tolerance to fetal alloantigens, which is necessary for successful pregnancy. Elevation in the level of pregnancy-related hormones including estrogen, progesterone and human chorionic gonadotropin promotes the recruitment and expansion of Tregs, directly implicating these cells in the regulation of fetal-maternal immune tolerance. Current studies have provided evidence that a defect in the number or function of Tregs contributes to the etiology of several reproductive diseases, such as recurrent spontaneous abortion, endometriosis, and pre-eclampsia. In this review, we provide insight into the underlying mechanism through which Tregs contribute to pregnancy-related immune tolerance and demonstrate the association between deficiencies in Tregs and the development of reproductive diseases.
Introduction
Regulatory T cells (Tregs), a key subset of T lymphocytes, play a critical role in regulating the immune response and maintaining immune tolerance both in physiological and pathological processes. Many studies have shown that Tregs are compromised in patients with autoimmune diseases as well as in patients with graft-versus-host disease after receiving transplanted organs (1), however, these cells are activated to promote tumor growth and progression, leading to the failure of immunotherapies in cancer (2). Defects in the number of Tregs and their suppressive activity are involved in the development of various systemic or organ-specific autoimmune diseases, including thyroiditis (3), gastritis (4), type I diabetes (T1D) (5), systemic lupus erythematosus (SLE) (6), multiple sclerosis (MS) (7), rheumatoid arthritis (RA) (8), and inflammatory bowel disease (IBD) (9).
During the course of pregnancy, the mother's systemic immune system is altered to tolerate the fetus, who expresses paternal major histocompatibility complex antigens. Many studies have supplied multiple lines of evidence that Tregs possess specific characteristics for preventing the development of a maternal immune response against the fetus and maintaining fetal-maternal tolerance. First, the proportion of Tregs in peripheral blood is significantly increased during pregnancy in both women and mice, and there is a specific recruitment of Tregs from maternal peripheral blood to the fetal-maternal interface, leading to a higher proportion of Tregs in the placental decidua than in the peripheral blood (10). Furthermore, a decreased proportion of Tregs has been proposed to be associated with pregnancy-related complication such as recurrent spontaneous abortion and pre-eclampsia (11–13). Second, antibody-mediated depletion of CD25+ Tregs has been shown to cause implantation failure in allogeneic mated mice (14). Conversely, the adoptive transfer of Tregs attenuates the high abortion rates in the well-studied CBA/J × DBA/2J abortion-prone murine model (15).
Pregnancy is a physiological process greatly dependent on immune tolerance, which is regulated by the number of Tregs and their suppressive activity. This review of the current literature describes the role played by Tregs in regulating fetal-maternal immune tolerance. Furthermore, we demonstrate the relationship between a deficiency of Tregs and pregnancy-related complications, with the aim of identifying the mechanisms through which Tregs maintain fetal-maternal immune homeostasis, thus providing a potential target for treating pregnancy-related complications.
Differentiation and Immunosuppressive Function of Tregs
Tregs are divided into two populations, namely natural regulatory T cells (nTregs) and inducible regulatory T cells (iTregs). NTregs originate from the thymus in response to self-antigens, whereas iTregs are peripherally induced from T cells responsible for restraining immune responses to foreign antigens, such as commensal bacteria, food antigens and allergens (16, 17). The mechanism underlying how Tregs are generated remains controversial. Although some studies have suggested that Tregs are anergic to TCR (T cell receptor) stimulation in vitro, the process involving the formation and selection of Tregs in the thymus is highly dependent on the TCR rearrangement, as evidenced by the observation that the development of Tregs is abrogated in TCR transgenic mice with RAG-2 deficiency (18). An increasing number of studies have suggested that Tregs are positively selected from autoreactive T cells that express specific TCR with the appropriate affinity for self-peptides (19–21).
Unlike other T helper cells, Tregs lack the capacity to secrete specific cytokines, and it is therefore difficult to distinguish them from other T helper cells. Foxp3 is the most specific Tregs marker and is constitutively expressed in Tregs generated in both the thymus and the periphery irrespective of the mode or state of activation (22, 23). The Foxp3 gene contains 11 exons and maintains a high degree of conservation between human and mouse genes (24). Mice genetically deficient in Foxp3 lose the ability to properly regulate Tregs activity and succumb to a fatal and severe lymphoproliferative autoimmune syndrome at 3–4 weeks of age (25). Similar to mice, humans carrying a FOXP3 mutant gene develop an autoimmune syndrome named IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) (26, 27). Beyond its role as an indispensable factor required for the development of Tregs, continuous Foxp3 expression is required for the latter's suppressive function. Research has shown that Tregs isolated from Foxp3 deficient mice lack suppressive function. However, transduction of Foxp3 endows CD4+CD25− T cells with the capacity to suppress the proliferation of CD4+ T cells (28, 29).
The suppressive function of Tregs is achieved via two mechanisms, namely a cell-contact dependent mechanism involving the recognition of co-stimulated molecules that directly suppress the expansion of effector T cells and a cell-contact independent mechanism involving the secretion of soluble cytokines that negatively regulate the immune response (30) (Figure 1).
Figure 1
The mechanisms underlying the suppressive function of Tregs. The suppressive function of Tregs is achieved via two mechanisms: cell-contact dependent mechanism and cell-contact independent mechanism. Tregs express a high-affinity IL-2 receptor and can competitively bind to IL-2 with Teffs, which induces IL-2 consumption and suppresses the development and expansion of Teffs. Both CD28 and CTLA4 interact with CD80/CD86 expressed on APCs. However, the affinity of CD28 is lower than that of CTLA4. CD28 plays an important role in enhancing Teffs activation, while CTLA4 acts as an inhibitor by depriving ligands and suppressing CD28 signaling. TGF-β and IL-10 are two classes of nonspecific cytokines secreted by Tregs and can promote Tregs expansion and suppressive activity by binding to their receptors.
Cell-Contact Dependent Mechanism
Cell-contact dependent suppressive activity is mediated via the recognition of co-stimulated molecules. In this process, Tregs function is highly dependent on the normal expression of molecules located on Tregs, and a deficiency of key molecules triggers the defective expansion and suppressive activity of Tregs, leading to a disturbance of immune homeostasis. IL-2 receptor α (IL-2Rα) and CTLA4 are the most important molecules involved in cell-contact dependent mechanism.
Most Tregs abundantly express high-affinity IL-2 receptor α (CD25) and IL-2/IL-2R signaling provides indispensable signaling during the development and maturation of Tregs both in the thymus and in the periphery. Furthermore, the lack of the IL-2R cannot be compensated by other cytokine receptors (31). IL-2, IL-2Rα, and IL-2Rβ deficient mice all die from severe lymphoproliferation and autoimmune disease in early life. In addition, neutralization of circulating IL-2 by anti–IL-2 monoclonal antibodies inhibits Tregs proliferation and triggers a wide range of organ specific autoimmune diseases (32–35). IL-2-IL-2R signaling is essential for the development and maturation of both Tregs and Teff cells, however, low dose IL-2 is remarkably efficacious in promoting the expansion of Tregs rather than Teff cells, which possibly results from the higher affinity of IL-2R in Tregs (36). Based on the comparative activity and different sensitivity for IL-2, the consumption of IL-2 by Tregs has been shown to be a predominant mechanism involved in suppressing the expansion and activity of Teff cells and triggering Teff cell apoptosis due to IL2 deprivation (37, 38).
CTLA4, a key molecule constitutively expressed in Tregs, is crucial for maintaining T cells homeostasis and tolerance induction, and its expression is in part controlled by Foxp3 (39, 40). Mice deficient in CTLA4 become sick by 2 weeks of age and moribund at 3–4 weeks of age, with diffuse and focal lymphocytic infiltration into various organs (41, 42). Furthermore, specific deficiency of CTLA4 in Tregs results in the spontaneous development of systemic lymphoproliferation, multi-organ lymphocyte infiltrations, fatal T cell-mediated autoimmune diseases, and hyperproduction of immunoglobulin E in mice (43). CTLA-4-mediated suppressive regulation of T cell response and upregulation of Tregs activation are predominantly achieved by competition with CD28, a positive costimulatory molecule that shares common ligands (CD80/CD86) with CTLA4 (44, 45). CTLA4 possesses significantly higher affinity in binding CD80/CD86 and CTLA4 rather than CD28 removes costimulatory ligands CD80/CD86 from APCs by a process of trans-endocytosis (46, 47). These properties equip CTLA4 with the capacity to outcompete the ability of CD28 to serve as a negative immune regulator (48, 49).
Cell-Contact Independent Mechanism
In addition to the cell-contact dependent mechanism, Tregs also exert suppressive activity in a cell-contact independent manner, mainly through the secretion of inhibitory cytokines. Unlike other T cells, Tregs fail to produce exclusive cytokines. However, certain cytokines, such as TGF-β and IL-10, secreted by Tregs are essential for the expansion and suppressive activity of Tregs.
Several lines of evidence suggest that the addition of TGF-β enhances the conversion rate of native T cells into Tregs, and that TGF-β secreted by Tregs plays a partial role in maintaining suppressive properties by binding to the TGF-β receptor (50–53). Administration of neutralizing antibodies specific for TGF-β or specific deficiency of TGF-β expression in Tregs leads to a limitation or even abrogation of Tregs' suppressive activity (54, 55). Strong evidence that the role of TGF-β to maintain Foxp3 expression is supported by the observation that the expression of Foxp3 is dramatically diminished in peripheral Tregs from TGF-β−/− mice and addition of TGF-β results in increased Foxp3 expression (52).
Unlike TGF-β, the function of IL-10 in Tregs seems to be organ-specific. Recent studies have found that IL-10 and IL-35 produced by intratumoral Tregs cooperatively share a common BLIMP1 axis to promote the exhausted intratumoral T cell state and anti-tumor immunity, implying IL-10 and IL-35 contribute to maintaining immune tolerance (56, 57). IL-10 is recognized as a potent suppressor of macrophage and T cell functions. Furthermore, IL-10 deficient mice are growth retarded and suffer from chronic enterocolitis (58). An increasing number of current studies have found that IL-10 is expressed in Tregs and plays an auxiliary role in promoting their expansion and function. IL-10+ Tregs are mostly located in intestinal tissues and are essential for limiting immune response-induced inflammation to the diverse intestinal microbiota, which may provide a reasonable explanation as to why IL-10 deficient mice or mice treated with anti-IL-10 receptor blockers succumb to intestinal inflammation (59, 60). Although the Tregs-specific deficiency in IL-10 does not result in severe systemic autoimmunity, it does lead to immunological hyperreactivity at environmental interfaces, resulting in conditions such as spontaneous colitis, lung hyperreactivity, and skin hypersensitivity (61). Thus, while IL-10 production by Treg cells is not necessary for the regulation of systemic autoimmunity, it is essential for hindering excessive immune responses at local environmental interfaces. The suppressive activity of IL-10 is partly mediated via binding to IL-10R to restrain the Th17-induced inflammatory response, which plays a critical role in regulating intestinal homeostasis. This is illustrated by the observation that mice with IL-10R deficient Tregs produce high levels of IL-17 and are prone to developing severe colitis (62, 63).
Regulation of Fetal-Maternal Tolerance During Healthy Pregnancy
For decades, many studies have shown that successful pregnancy depends on the homeostasis of fetal-maternal tolerance. Furthermore, failure of the maternal immune system to establish fetal-maternal tolerance is the predominant trigger in the development of pregnancy-related complications. Consequently, numerous therapeutic treatments aimed at suppressing the maternal immune system are employed in clinics. However, the effect of these therapies is not always apparent and is often accompanied by various side effects. It is therefore important to identify the cellular and molecular mechanisms responsible for establishing fetal-maternal immune tolerance in healthy and abnormal pregnancies to promote the development of targeted therapeutic interventions. The immune suppressive property of Tregs confers this cell population with a fundamental role in establishing the fetal-maternal immune tolerance necessary for successful pregnancy.
Some studies consider pregnancy to be a process of mutual conversion between pro-inflammatory and anti-inflammatory conditions (64), therefore dividing pregnancy status into three distinct immunological states that correspond to different stages of fetal development: first, a pro-inflammatory stage associated with embryo implantation and placentation (65–67); second, an anti-inflammatory-oriented stage associated with fetal growth (68, 69); and third, a switch from an anti-inflammatory to a pro-inflammatory stage necessary for the initiation of labor (70, 71). Concurrent with the above stages is a dramatic change in the number of Tregs during the course of pregnancy. Following exposure of paternal alloantigens, circulating Tregs increase rapidly during the early pregnancy stage and peak during the second stage at which time trophoblast invasion of the maternal decidua is maximal; then, Tregs gradually decrease when labor begins (64). The change in the number of Tregs and crosstalk with other immune cells play a critical role throughout the entire course of pregnancy.
Tregs Priming and Implantation
Embryo implantation is the initial stage of pregnancy and involves apposition of the blastocyst and the uterine endometrium followed by attachment and invasion of the blastocyst into the endometrium, and reconstruction of the decidua by the invasive trophectoderm (72). The wide application of assisted reproductive technology, such as in vitro fertilization-embryo transplantation (IVF-ET) and intrauterine insemination (IUI), has enabled an analysis of earlier gestational stages from oocyte fertilization to implantation in humans. Adequate endometrial receptivity is considered a pivotal precondition for successful embryo implantation. Endometrial scratching before embryo transfer has been proposed as a clinical treatment to increase uterine receptivity, and some studies have demonstrated that endometrial scratching improves the pregnancy outcome by triggering an inflammatory response and enhancing angiogenesis at the implantation site, providing indirect evidence for the role played by inflammation during implantation (73–77).
Studies based on human and animal experiments have demonstrated that the peri-implantation period is accompanied with the activation and infiltration of various immune cells (78). Uterine-specific natural killer (uNK) cells, macrophages (Mos), and dendritic cells (DCs) are recruited at the implantation site and exert prominent immune-regulatory effects during early pregnancy. uNK cells are the most abundant immune cells located in human decidua during early pregnancy, while Mos and DCs serve as antigen-presenting cells that infiltrate into the decidua. Crosstalk among these cells plays an essential role in regulating trophoblast invasion and in promoting spiral artery remodeling (79–81).
The role played by Tregs during implantation is unclear. However, some studies have reported that a reduced number of Tregs is associated with implantation failure. Mice with a depletion of Tregs exhibit a significant defect in implantation, which is reversed following an adoptive transfer of Tregs (82). A study showed that compared with fertile women, endometrial tissue from women with unexplained infertility displayed a significant reduction Foxp3 mRNA expression, the fate-determining transcription factor especially expressed in Treg cells (83). Other evidence has also revealed a correlation between the level of Tregs in peripheral blood and the implantation rate. Women with implantation failure after IVF or artificial insemination by donor sperm (AID) had a significantly decreased percentage of Tregs compared with women with a successful pregnancy (84, 85). Therefore, the presence of peripheral or local Tregs may create a limited but necessary immunomodulatory function during the course of implantation.
Enlargement OF Tregs Function and Pregnancy Maintenance
Successful implantation is followed by a phase of fetal growth and development. The establishment of fetal-maternal immune tolerance lays the foundation for this stage, with a shift from a pro-inflammatory immune response to a Th2/Treg-predominant anti-inflammatory immune tolerance (64). The proportion of Tregs begins to rise and peaks at this stage, and a paucity of Tregs could lead to pregnancy-related complications such as spontaneous abortion. Tregs exert a strong immunosuppressive function to maintain an anti-inflammatory environment and protect the fetus from maternal immunological rejection. Tregs can effectively suppress the expansion and activation of effector T cells via a classic cell-contact mechanism or by secreting suppressive cytokines as described previously. One study described a class of functionally distinct Tregs with expression of a co-inhibitory molecule TIGIT, which induces selective suppression of Th1 and Th17 cells but not Th2 cells. However, whether this Tregs subset is expanded and activated during pregnancy is still unknown (86).
The pivotal role played by Tregs in fetal-maternal tolerance raises several questions about the mechanisms responsible for their expansion during pregnancy and underscores the need for studies investigating these mechanisms. Previous studies suggest that the activation and regulation of Tregs is primarily impacted by antigen exposure and the dynamic changes of steroid hormones that occur during pregnancy.
Antigen-Mediated Tregs Expansion: Paternal Sperm Antigen and Fetal Antigen
Investigators have proposed that exposure to male seminal fluid delivered during mating elicits the expansion of maternal Tregs, as evidenced by the increase in the number of Tregs within the period of time subsequent to mating and before embryo implantation (87, 88). Immune tolerance to the fetus is necessary for successful pregnancy, and transmission of seminal fluid seems to play a priming role prior to implantation by promoting expansion of Tregs, thereby activating specific tolerance to paternal alloantigens. Seminal fluid contains various components, including a cellular fraction that contains sperm, leukocytes and epithelial cells and a non-cellular fraction of compounds such as TGF-β and prostaglandins. The cellular and acellular fractions in semen both contain several antigens, including classical class Ia, non-classical class Ib and minor antigens such as H-Y antigen, which drive an antigen-dependent expansion of Treg cells (89, 90). The non-cellular components are also required to confer tolerance. As mentioned above, TGF-β is a critical cytokine for Tregs proliferation. One study found that intravaginal pre-treatment with TGF-β at mating enhances successful pregnancy in vivo in a well-established murine model (91). An in vitro experiment also indicated a role for prostaglandins in upregulating Foxp3 expression and enhancing Tregs function (92). Collectively, both sperm and seminal plasma may contribute to driving an expansion of Tregs and providing an immune-privileged environment that is beneficial for subsequent embryo implantation.
Embryo implantation and fetal growth are the most important stages during pregnancy. Some studies have proposed that the implanted blastocyst should be considered a semi-allograft and constant immunosuppression is required for a pregnancy to be successful. Although a seemingly opposite pro-inflammatory process is involved in both implantation and initiation of labor, immunosuppression is an indispensable response to maintain immune homeostasis during the fetal growth stage, and this is highly dependent on the expansion and activation of Tregs triggered by the fetal alloantigens (93). When Tregs are depleted, fetal outcome is normal in syngeneic pregnancies rather than allogeneic pregnancies, suggesting that Tregs suppress maternal immune responses directed against fetal alloantigens rather than male-specific minor histocompatibility antigens (94, 95). When encountered with parental alloantigens presented by a fetus, peripheral Tregs, generated extrathymically and induced by non-self-antigens, serve as the predominant subset suppressing immune response. The development of peripheral Tregs is dependent on the expression of a Foxp3 enhancer CNS1, a deficiency of which leads to an increased resorption of embryos in mice (96).
Steroid Hormone-mediated Tregs Expansion: Estrogen, Progesterone and Human Chorionic Gonadotropin
Serum levels of the pregnancy-associated hormones such as estrogen, progesterone, and human chorionic gonadotropin (HCG) increase dramatically during pregnancy. These hormones play an essential role in maintaining immune tolerance and in supporting successful pregnancy. Currently, there is increasing evidence that the mechanisms through which hormones contribute to immune homeostasis during pregnancy are in part due to the expansion of Tregs and their suppressive activity (Figure 2).
Figure 2
Pregnancy-related hormones affect the expansion and migration of Tregs. The levels of various steroid hormones, such as estrogen, progesterone and human chorionic gonadotropin, change dramatically during pregnancy. Estrogen and progesterone promote Tregs expansion and trigger the conversion of CD4+CD25– T cells to Tregs separately by binding to estrogen and glucocorticoid receptors. The level of human chorionic gonadotropin (HCG), another essential hormone for maintaining a healthy pregnancy, begins to increase after fertilization, peaks at the 11th week, and then gradually decreases until birth. HCG functions as a regulator that not only upregulates the expansion of Tregs but also provokes migration of Tregs from the circulation to the decidua.
Estrogen-based therapy has been reported to alleviate symptoms associated with several autoimmune diseases, such as collagen-induced arthritis (97), type1diabetes (98), and autoimmune encephalomyelitis (99). Furthermore, the mechanisms underlying these protective effects seem to be associated with changes in immune cells and cytokines (100–102). The number of Tregs in human peripheral blood change continuously during the menstrual cycle and peak before ovulation, which is concurrent with the change of the concentration of estrogen, suggesting that estrogen may be a powerful factor in promoting Tregs expansion (103). Some studies have demonstrated that the proliferation and suppressive activity of human Tregs observed with estrogen treatment is mediated through estrogen receptor α (104, 105). In both in vivo and in vitro experiments, estrogen treatment triggers the expansion of Tregs. Furthermore, the addition of estrogen in combination with TCR stimulation enhances Foxp3 mRNA expression in CD4+CD25−T cells in vitro, suggesting that estrogen may potentially induce the conversion of CD4+CD25−T cells to Tregs (106, 107).
Progesterone, which is mainly produced by the placenta and is markedly elevated during pregnancy, functions as a regulator that maintains homeostasis at the maternal-fetal interface. Similar to estrogen, progesterone is considered to be another important hormone that promotes the expansion of Tregs and their suppressive capacity (107). The proportion of Tregs and the conversion rate of CD4+CD25− T cells into Tregs has been shown to increase significantly in the peripheral blood, spleen, and inguinal lymph nodes of ovariectomized mice after progesterone injection (108). Progesterone-mediated immune tolerance is achieved by progesterone binding to the glucocorticoid receptor rather than to the progesterone receptor (109, 110). Progesterone promiscuously binds the glucocorticoid receptor and promotes immune suppression by inducing enrichment of Treg cells and triggering apoptosis of effector T cells, which is based on the preferred sensibility in effector T cells for glucocorticoid receptor-mediated T cells death compared with that in Tregs (110, 111). Progesterone is also present at high levels in human cord blood where it has been reported to have an immune-suppressive function. Progesterone drives a shift of native cord blood T cells into suppressive Tregs, while impeding the conversion from native T cells into Th17 cells, another potential pathway through which progesterone regulates immune tolerance (112).
HCG is another hormone that is increased during pregnancy, and is produced in the blastocyst after fertilization, reaching its maximum level at the 11th week and then gradually decreasing until birth (113). Khil et al. reported that HCG prevents the development of autoimmune-mediated diabetes in NOD mice by downregulating immune effector cells and cytokines and simultaneously upregulating the proportion of Tregs and the levels of TGF-β and IL-10, suggesting that HCG is an effective regulator for immune tolerance (114). Increased HCG during pregnancy provokes many Tregs-related responses including (1) augmenting the number of Tregs, (2) increasing their local and systemic suppressive function, (3) enhancing attraction of circulating Tregs into decidua, and (4) increasing the secretion of suppressive cytokines (115–117). HCG-mediated expansion of Tregs is achieved in part by retaining DCs in an immature state, leading to the generation of Tregs and a loss of the capacity to activate a T cell-mediated immune response (117, 118). In vitro migration assays further confirmed the chemoattractant properties of HCG that promote migration of Tregs from the periphery into the uterus, which is potentially mediated via binding to HCG/LH receptors located on Tregs (116, 119).
Decline of Tregs Activity and Labor
There is a decline in the number of Tregs as pregnancy progresses into the third gestational period. The reduction in the number of Tregs in late gestation may be a contributing factor for the initiation of spontaneous labor. This is supported by the finding that the proportion of Tregs in the decidua following a spontaneous vaginal delivery is significantly lower than that following an elective cesarean section (120). Shah et al. conducted a longitudinal analysis from 20-weeks gestational age to labor and observed a reduction in the number of activated Tregs (defined as Tregs with HLA-DR+) and a significant shift toward a Th1/Th17 response with the onset of labor (121). Compared with women undergoing spontaneous term labor, the proportion of activated Tregs is significantly decreased in women in preterm labor (122, 123). The change is similar to the reduction in activated Tregs observed in patients who experience an acute rejection after kidney transplantation, supporting that the reduction in the proportion and activity of Tregs promotes the conversion from an anti-inflammatory to a pro-inflammatory stage and plays a critical role in initiating spontaneous labor. The mechanism underlying the reduction in Tregs during labor remains an enigma. The alteration in hormone levels and in the microbial environment may be stimuli for activating an inflammatory response, however, the specific molecular mechanisms needs to be further investigated.
The level of Tregs progressively decreases after delivery. However, there is a retention of “memory” Tregs with fetal specificity, which retain the ability to generate a more effective and accelerated suppressive response when re-exposed to the same fetal antigens in subsequent pregnancies (124). The primary pregnancy confers Tregs with a protective regulatory memory, which may provide an immunological basis for protection against complications such as pre-eclampsia in a subsequent pregnancy (125, 126).
Dysfunction of Tregs in Reproductive Diseases
Since it has been determined that Tregs maintain fetal-maternal tolerance during the normal course of embryo implantation and pregnancy, it is of interest to investigate whether systemic and local maldistribution and dysfunction of Tregs play a role in the etiology of infertility and pregnancy-related complications. Increasing evidence suggests that a deficiency in the expansion and function of Tregs as well as an abnormal expression of key molecules are linked to pregnancy-related complications.
Recurrent Spontaneous Abortion
Recurrent spontaneous abortion (RSA), defined as the loss of three or more consecutive pregnancies, affects ~1% of women attempting to conceive (127, 128). RSA is a complex pregnancy-related complication that is due to multiple factors including chromosomal abnormalities, congenital or acquired anatomical defects in the uterine fundus and cervix, and other endocrine diseases such as PCOS, diabetes, thyroid disorders, and others related to aberrant immune responses (128, 129). Increasing evidences suggests that the proportion of various immune cells and cytokines is altered in patients with RSA, supporting that immune dysfunction may be a contributing factor to its etiology (130, 131). Although there have been detailed guidelines describing clinical interventions for managing women with RSA, treatment based on immune rejection as a potential etiology is controversial, because no definite cellular and molecular mechanism has been discovered to date (17, 129).
The mechanisms through which Tregs contribute to RSA primarily involve an imbalance of the Th1/Th2/Th17/Treg cells paradigm and the abnormal proportion and activity of Tregs. Dysregulation of T lymphocyte homeostasis is also involved in the etiology of RSA. In peripheral blood from patients with RSA, the balance between Th1 and Th2 cells is disrupted in favor of Th1 cells, and the ratio of Th17/Treg cells is skewed toward Th17 cells (132, 133). It is widely accepted that there is a close interaction between the expansion of Tregs and the secretion of IL-17. When IL-17 combines with the IL-17 receptor, Tregs are upregulated. Conversely, Tregs suppress the proliferation of Th17 cells and the secretion of IL-17 via cell-cell contact and via Il-10/TGF-β-mediated effects (134, 135). However, this suppressive function of Tregs is abrogated in patients with RSA (134). Transfusion of Tregs into mice pretreated with IL-17 has been shown to significantly increase the expression of IL-10 and TGF-β, two key cytokines that mediate the suppressive activity of Tregs in decidua and lower the fetal resorption rates in mice (136). Furthermore, insufficient generation of pregnancy-induced Tregs triggers the accumulation of paternal alloantigen specific Th1 cells and directly results in the failure to establish appropriate maternal-fetal immune tolerance (137).
Numerous studies have also confirmed that the reduction in the number of Tregs are involved in the pathogenesis of RSA (Table 1). Sasaki et al. first reported the presence of Tregs in the decidua and demonstrated the proportion of Tregs in decidua from spontaneous abortions was significantly lower than that in decidua from induced abortion (11). Other studies have also demonstrated that the proportion of Tregs and the expression of Foxp3 in both the decidua and peripheral blood from patients with unexplained RSA patients are significantly lower than those from women with normal pregnancies (13, 139). In addition to the reduction in number, Lourdes et al. reported that the suppressive function of Tregs is significantly impaired in RSA as assessed by a co-culture technique with CD4+CD25−T cells (103). Inadequate number of Tregs and downregulation of Treg cell activity impair the anti-inflammatory environment, weaken the immune tolerance against fetal rejection and thereby increase the risk of RSA.
Table 1
| Proportion of Tregs | References | |
|---|---|---|
| Peripheral blood | Decidua | |
| ↓ | ↓ | (11) |
| ↓ | ↓ | (13) |
| ↓ | ↓ | (138) |
| ↓ | ↓ | (139) |
| ↓ | Not mentioned | (132) |
| ↓ | Not mentioned | (140) |
| Not mentioned | ↓ | (141) |
| ↓ | Not mentioned | (142) |
| ↓ | ↓ | (143) |
The change of the proportion of Tregs in patients with recurrent spontaneous abortion compared with normal pregnant women.
↓: Decreased.
Endometriosis
Endometriosis is a benign gynecological disease affecting ~6–10% women of childbearing age, and is characterized by the implantation of endometrial tissues outside the uterus (144). Chronic pelvic pain, dysmenorrhea and infertility are the common symptoms occurring in patients with endometriosis (145, 146). As multiple factors, including genetic and environmental factors, contribute to the development of endometriosis, the pathogenesis of endometriosis remains uncertain. Many theories have been proposed to explain how endometriosis develops, and one of the most widely accepted is the retrograde menstruation theory. This theory hypothesizes that fragments of endometrial tissue reflux to the peritoneum through the fallopian tubes during menstruation (147). However, this theory fails to explain why only a few women develop endometriosis even though retrograde menstruation is a common phenomenon occurring in most women of childbearing age (148). Therefore, other studies have postulated that a disturbed local and systemic immune response may be responsible for the development and progression of endometriosis (149–151).
An aberrant immune environment that includes alternative activation of peritoneal macrophages (152), production of various cytokines (153), and reduction in natural killer cell cytotoxicity (154), all contribute to the survival and invasion of ectopic endometrial tissue. Dysregulation in T lymphocyte homeostasis is associated with the pathogenesis of endometriosis. The Th1/Th2 balance is altered in local and systemic immune conditions, such that there is skewing toward Th2 cells in endometriotic lesions, but skewing toward Th1 cells in peripheral blood (155).
A disturbance in Tregs activity may be a more prominent mechanism involved in the etiology of endometriosis due to their immune-suppressive function, derangement of which could potentially promote the survival of ectopic endometrial lesions. However, evidence regarding the change in the proportion of Tregs in peripheral blood, peritoneal fluid, eutopic endometrium, and ectopic endometrial tissues among patients with endometriosis is inconsistent (Table 2). The discrepancy may result from differences in patient selection, namely the patients with early or advanced endometriosis. Most studies suggest the proportion of Tregs is significantly increased in peritoneal fluid from women with endometriosis compared with control women (157, 158, 161). One study reported that the number of Tregs was increased in the peritoneal fluid and decreased in the peripheral blood, and another study found the number of Tregs was higher in peritoneal fluid than in peripheral blood, both indicating that active translocation of Tregs occurs from circulation to the local peritoneal cavity (158, 162). However, some studies failed to find any difference in the proportion of Tregs in patients with endometriosis when compared with women without endometriosis (159). To bypass the confounding influence of interpatient variability, research has been carried out in an established animal model with endometriosis to identify abnormalities in the proportion of Tregs. In a study of baboons with induced endometriosis, the proportion of Tregs was decreased in peripheral circulation and eutopic endometrium but increased in ectopic tissue, which is consistent with Tregs' local immunosuppressive activity Tregs played (163). Tanaka et al. focused on the variation in resting and activated Tregs and put forth a new concept that the proportion of activated Tregs in the endometrioma rather than in the peritoneal fluid or peripheral blood is decreased, which may be temporal and associated with the angiogenesis and progression of endometriosis (160). However, a study showed the proportion of Tregs in ectopic endometrium was increased in patients with endometriosis compared with eutopic endometrium (156). Further research is required with an expanded sample size and more detailed subgroup analysis to better determine the role Tregs play in the pathogenesis of endometriosis.
Table 2
| Proportion of Tregs in patients with endometriosis | References | ||
|---|---|---|---|
| Peripheral blood* | Peritoneal fluid* | Ectopic peritoneal lesions# | |
| Not mentioned | Not mentioned | ↑ | (156) |
| Not mentioned | ↑ | Not mentioned | (157) |
| ↓ | ↑ | Not mentioned | (158) |
| → | → | Not mentioned | (159) |
| → | Not mentioned | Not mentioned | (155) |
| → | → | ↓ | (160) |
| → | ↑ | Not mentioned | (161) |
| → | → (Early) ↑(Advanced) | Not mentioned | (162) |
The change of the proportion of Tregs in patients with endometriosis compared with patients without endometriosis.
↑: Increased, ↓: Decreased, → : Not changed.
The proportion of Tregs in peripheral blood and peritoneal fluid in patients with endometriosis is compared with patients without endometriosis.
The proportion of Tregs in the ectopic peritoneal lesions in patients with endometriosis is compared with eutopic endometrium in patients without endometriosis.
Change in the proportion of Tregs appears to contribute to the suppressed immune response against ectopic endometrial tissue, permitting implantation of endometrial tissue in the peritoneal cavity. Therefore, understanding the origin of local Tregs production may be provide new insights that will aid in the development of targeted therapies for women with endometriosis. The accumulation of Tregs in the peritoneal cavity may not only be a result of active translocation from the peripheral blood but may also be due to their local induction (153). Higher levels of IL-10 and TGF-β, two key cytokines responsible for regulating the proliferation and activity of Tregs, were found in the peritoneal fluid and serum of patients with endometriosis than in normal controls (164, 165). Compared with serum levels, the level of cytokines in peritoneal fluid was significantly higher (165). Furthermore, IL-10 and TGF-β mRNA expression were significantly higher in ectopic lesions than eutopic endometrium from women with or without endometriosis, particularly in cases of advanced endometriosis (166). These results suggest Tregs and related cytokines maintain the local anti-inflammatory environment and play a crucial role in the development of endometriosis.
Preeclampsia
Preeclampsia is a common pregnancy-related complication that occurrs in 3–5% of pregnant women and can lead to iatrogenic preterm birth and fetal growth restriction (167). The precise etiology of preeclampsia remains unknown, although insufficient formation of uterine spiral arteries, over-activated inflammation, injured endothelial cells, and genetic factors have all been implicated (168–171). Interestingly, preeclampsia seems to be more common in primiparous than multiparous women, whereas the protective effect is abrogated with the change of partner. A meta-analysis compared the difference in the risk of preeclampsia in women who were impregnated by donor or partner sperm and found the risk was significantly increased in conceptions resulting from donor sperm (172). Furthermore, another study reported that prior and prolonged partner sperm exposure before pregnancy is associated with a significant reduction of the risk of preeclampsia (173). Taken together, these observations suggest that paternal antigens and sperm exposure induce an immune tolerance during the first pregnancy and offer effective protection against the development of preeclampsia with subsequent pregnancies, implying the adaptive immune response with alloantigen specificity and immunological memory is involved in the pathogenesis of preeclampsia (174).
An increasing body of evidence suggests that an inadequate immune tolerance induced by Tregs-associated abnormalities play a pivotal role in the etiology of preeclampsia. Several studies have reported that, compared with normal pregnancy, both the number of Tregs and the ratio of Tregs to Th17 cells in peripheral blood are significantly reduced in preeclampsia (175–177). The increased ratio of Th17/Treg cells has also been confirmed by an analysis of Th17/Treg expression of related transcription factors and the secretion of Th17/Treg-related cytokines. Compared with healthy pregnant women, a reduction in the expression of Treg-specific transcription factor Foxp3 and an elevation in Th17-specific transcription factor RORγt in patients with preeclampsia has been reported (178). Furthermore, analysis of cytokine profiles have revealed a significant decrease in IL-10, and a significant increase in IL-17 levels in patients with preeclampsia (178, 179). Taken together, these studies suggest that a shift occurs from Tregs to Th17 cells in the development of preeclampsia, leading to an abnormal immune state that triggers inflammation and an impairment of immune tolerance. The mechanism underlying the imbalance of Th17/Treg cells remains unclear. Eghbal-Fard et al. suggested the upregulation of miRNA in patients with preeclampsia may affect the differentiation and expansion of Th17/Treg cells by regulating the expression of specific transcription factors (178). In addition to the alteration in the proportion of Tregs, the immunosuppressive activity of Tregs is also altered in patients with preeclampsia. Darmochwal-Kolarz et al. reported the proliferation of effector T lymphocytes in patients with preeclampsia was significantly inhibited by Tregs isolated from healthy pregnant women. However, the suppressive response was lost if replaced with Tregs from patients with preeclampsia (180).
The recruitment of Tregs from peripheral blood into decidua and the local expansion of decidual Tregs are important for maintaining fetal-maternal immune tolerance at the fetal-maternal interface. It has been well-established that the proportion of Tregs in decidua is decreased in preeclampsia (181). Though the reduction of decidual Tregs may be associated with an imbalance in systemic Tregs, local expansion may also play an important role. TCR repertoire analysis of decidual Tregs showed an insufficient clonal expansion of decidual Tregs in preeclampsia compared with healthy pregnancy (182). In normal pregnancy, induced rather than native Tregs are the dominant Tregs subset located in the decidua and are clonally expanded, while the expansive and suppressive capacity of iTregs is significantly impaired in preeclampsia (183). The local induction of Tregs depends on specific APCs within the decidual microenvironment. A significant reduction in the expression of HLA-G and ILT4 on decidual APCs is observed in preeclampsia compared with normal pregnancy, providing a possible clue to the lack of iTregs in preeclampsia (183). An aberrant proportion and type of Tregs in the decidua disturb the immune homeostasis during pregnancy and promote the development of preeclampsia.
Tregs and Immune Therapy During Pregnancy
Taken together, the above studies suggest that Tregs play a prominent role in regulating fetal-maternal immune tolerance, and a defect in the proportion and activity of Tregs is involved in the development of RSA, endometriosis, and preeclampsia. Thus, approaches designed to boost the proportion of Tregs or strengthen their suppressive function may lead to promising strategies for treating pregnancy-related diseases. Several Tregs-based target therapies are entering into clinical trials, including adoptive Treg cell therapy, Tregs-enhancing drugs, and low dose IL-2 administration (184).
Administration of purified Tregs was firstly applied as Tregs-based target therapy. With the development of immune cell therapy, antigen-specific Tregs therapy was also proposed for treating autoimmune and graft-versus-host diseases. Phase I/II clinical trials aimed to explore the curative effect, and some have reported that Tregs administration alleviates clinical symptoms induced by autoimmunity (184). Some research has attempted to determine whether Tregs administration improves pregnancy outcomes. Yin et al. and Wang et al. examined the effectiveness of adoptive transfer of Tregs in preventing spontaneous abortion in mice models (136, 185). Yin et al. established an abortion-prone pregnancy mice model with DBA/2J-mated pregnant CBA/J mice and performed adoptive transfer of freshly isolated and in vitro expanded Tregs from non-pregnant CBA/J mice. Wang et al. induced spontaneous abortions by administration of IL-17 in a CBA/J × BALB/c mouse model of normal pregnancy and performed adoptive transfer of in vitro expanded Tregs purified from pregnant CBA/J mice. These two studies demonstrated transfusion with in vitro expanded Tregs promotes immune suppressive activity, increases the secretion of suppressive cytokines and significantly reduces the rate of spontaneous abortion.
Although Treg cell therapy has not been widely used in clinical practice, clinical research has initiated several non-specific immunotherapies partially regulating the proportion and activity of Tregs for the treatment of pregnancy-related diseases. Intravenous immunoglobulin G (IVIG) and paternal or third-party lymphocyte immunization therapy have been proposed for the treatment of patients with RSA due to the potential immunomodulatory effects. Although the benefit for these immunotherapies is controversial, a growing body of evidence suggests that they may increase rates of live birth and decrease rates of miscarriage (186–188). A variety of studies and clinical trials have reported both IVIG and lymphocyte immunization therapy correct the Tregs defect and rebalances the Th17/Treg paradigm in peripheral blood. Compared with a control group, the treatment triggers a shift toward Tregs in the Th17/Treg balance by enhancing the expansion of Tregs, promoting the secretion of suppressive cytokines, and inhibiting Th17 cells proliferation (186, 188–192).
Tregs-enhancing drugs are another type of Tregs-based target therapy. Rapamycin (Sirolimus) is an mTOR inhibitor, which acts as an immunosuppressive drug by selectively promoting the expansion of Tregs and inducing differentiation of T helper cells into Tregs. Royster et al. established a murine model with conditional knockdown of Tregs induced by diphtheria toxin. They found the deletion of Tregs decreased litter sizes and triggered embryo implantation failure, effects that were reversed after the treatment with rapamycin (193). A multicenter, double-blind, phase II randomized clinical trial administrated 2 mg/day of sirolimus for 2 days before embryo transfer to patients receiving IVF-ET therapy and who had a history of recurrent implantation failure. The study collected blood samples and assessed the ratio of Th17/Treg cells by flow cytometry 5–10 days prior to the initiation of an IVF cycle. Only patients with a high ratio of Th17/Treg cells were included in this trial. The trial reported that the administration of sirolimus reversed the imbalance in the ratio of Th17/Treg cells and significantly increased the rate of clinical pregnancy and live birth compared with those in the control group (194).
Taken together, some studies have demonstrated the effectiveness of Tregs-based therapy in treating several autoimmune diseases and cases of organ transplantation. However, the methods cannot be directly applied for pregnancy-related diseases because the dynamic change in the immune state during pregnancy and the possibility of fetal drug toxicity must be taken into account. Most of the current treatments for pregnancy-related diseases focus on a reduction in an overactive immune response with the use of non-specific immunosuppressive therapy. This triggers the simultaneous activation of numerous immune cells and makes it difficult to control the dose and to evaluate the curative effect because of individual heterogeneity. Therefore, more studies should be conducted to further explore the effectiveness and safety of Tregs-based target therapies for the treatment of pregnancy-related diseases.
Conclusion and Future Perspective
Tregs are generally viewed as arising from a specific T cell lineage generated in the thymus or induced in peripheral organs. Being the most predominant immune-suppressive cells, a tremendous amount of research has focused on determining the molecular mechanisms responsible for inducing the expansion of Tregs and their activity in the periphery and in specific organs. This effort will provide new insights that will guide the improvement of Tregs-based targeted immune therapy. In recent years, increasing data has shown that the expansion of Tregs is triggered after exposure to the fetal alloantigens and changes dynamically over the course of pregnancy. Hormones such as estradiol and progesterone as well as HCG are significantly increased during pregnancy, and regulate the number and function of Tregs to sustain a proper pregnancy-related immune tolerance. Furthermore, various reproductive diseases such as recurrent miscarriage, endometriosis and preeclampsia result in part from the deficiency in the number and activity of Tregs. Therefore, modulating the immune response by boosting the number of Tregs and enhancing their activity may be a potential therapeutic strategy for managing these pregnancy-related complications.
Statements
Author contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Funding
This work was supported by National Natural Science Foundation of China (Grant No. 81871212).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
KorethJMatsuokaKKimHTMcDonoughSMBindraBAlyeaEPet al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. (2011) 365:2055–66. 10.1056/NEJMoa1108188
2.
PlitasGKonopackiCWuKBosPDMorrowMPutintsevaEVet al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity. (2016) 45:1122–34. 10.1016/j.immuni.2016.10.032
3.
EllisJSHongSHZaghouaniHBraley-MullenH. Reduced effectiveness of CD4+Foxp3+ regulatory T cells in CD28-deficient NOD.H-2h4 mice leads to increased severity of spontaneous autoimmune thyroiditis. J Immunol. (2013) 191:4940–9. 10.4049/jimmunol.1301253
4.
HarakalJRivalCQiaoHTungKS. Regulatory T cells control Th2-dominant murine autoimmune gastritis. J Immunol. (2016) 197:27–41. 10.4049/jimmunol.1502344
5.
SerrIFurstRWAchenbachPSchermMGGokmenFHauptFet al. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice. Nat Commun. (2016) 7:10991. 10.1038/ncomms10991
6.
LaiZWKellyRWinansTMarchenaIShadakshariAYuJet al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. (2018) 391:1186–96. 10.1016/S0140-6736(18)30485-9
7.
International Multiple Sclerosis Genetics Consortium. Low-frequency and rare-coding variation contributes to multiple sclerosis risk. Cell. (2018) 175:1679–1687.e7. 10.1016/j.cell.2018.09.049
8.
KomatsuNOkamotoKSawaSNakashimaTOh-horaMKodamaTet al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. (2014) 20:62–8. 10.1038/nm.3432
9.
LeberAHontecillasRZoccoli-RodriguezVChauhanJBassaganya-RieraJ. Oral treatment with BT-11 ameliorates inflammatory bowel disease by enhancing regulatory T cell responses in the gut. J Immunol. (2019) 202:2095–104. 10.4049/jimmunol.1801446
10.
TilburgsTRoelenDLvan der MastBJdeGroot-Swings GMKleijburgCScherjonSAet al. Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol. (2008) 180:5737–45. 10.4049/jimmunol.180.8.5737
11.
SasakiYSakaiMMiyazakiSHigumaSShiozakiASaitoS. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod. (2004) 10:347–53. 10.1093/molehr/gah044
12.
SasakiYDarmochwal-KolarzDSuzukiDSakaiMItoMShimaTet al. Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol. (2007) 149:139–45. 10.1111/j.1365-2249.2007.03397.x
13.
YangHQiuLChenGYeZLuCLinQ. Proportional change of CD4+CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients. Fertil Steril. (2008) 89:656–61. 10.1016/j.fertnstert.2007.03.037
14.
ShimaTSasakiYItohMNakashimaAIshiiNSugamuraKet al. Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice. J Reprod Immunol. (2010) 85:121–9. 10.1016/j.jri.2010.02.006
15.
ZenclussenACGerlofKZenclussenMLRitschelSZambon BertojaAFestSet al. Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur J Immunol. (2006) 36:82–94. 10.1002/eji.200535428
16.
ZhangHKongHZengXGuoLSunXHeS. Subsets of regulatory T cells and their roles in allergy. J Transl Med. (2014) 12:125. 10.1186/1479-5876-12-125
17.
WilliamsZ. Inducing tolerance to pregnancy. N Engl J Med. (2012) 367:1159–61. 10.1056/NEJMcibr1207279
18.
ItohMTakahashiTSakaguchiNKuniyasuYShimizuJOtsukaFet al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. (1999) 162:5317–26.
19.
JordanMSBoesteanuAReedAJPetroneALHolenbeckAELermanMAet al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. (2001) 2:301–6. 10.1038/86302
20.
KawahataKMisakiYYamauchiMTsunekawaSSetoguchiKMiyazakiJet al. Generation of CD4(+)CD25(+) regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression. J Immunol. (2002) 168:4399–405. 10.4049/jimmunol.168.9.4399
21.
LiMORudenskyAY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. (2016) 16:220–33. 10.1038/nri.2016.26
22.
FontenotJDGavinMARudenskyAY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. (2003) 4:330–6. 10.1038/ni904
23.
FontenotJDRasmussenJPWilliamsLMDooleyJLFarrAGRudenskyAY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. (2005) 22:329–41. 10.1016/j.immuni.2005.01.016
24.
LuLBarbiJPanF. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. (2017) 17:703–17. 10.1038/nri.2017.75
25.
BrunkowMEJefferyEWHjerrildKAPaeperBClarkLBYasaykoSAet al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. (2001) 27:68–73. 10.1038/83784
26.
BennettCLChristieJRamsdellFBrunkowMEFergusonPJWhitesellLet al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. (2001) 27:20–1. 10.1038/83713
27.
GavinMATorgersonTRHoustonEDeRoosPHoWYStray-PedersenAet al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA. (2006) 103:6659–64. 10.1073/pnas.0509484103
28.
HoriSNomuraTSakaguchiS. Control of regulatory T cell development by the transcription factor Foxp3. Science. (2003) 299:1057–61. 10.1126/science.1079490
29.
KhattriRCoxTYasaykoSARamsdellF. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. (2003) 4:337–42. 10.1038/ni909
30.
PaustSLuLMcCartyNCantorH. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA. (2004) 101:10398–403. 10.1073/pnas.0403342101
31.
ToomerKHLuiJBAltmanNHBanYChenXMalekTR. Essential and non-overlapping IL-2Ralpha-dependent processes for thymic development and peripheral homeostasis of regulatory T cells. Nat Commun. (2019) 10:1037. 10.1038/s41467-019-08960-1
32.
MalekTRYuAVincekVScibelliPKongL. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. implications for the nonredundant function of IL-2. Immunity. (2002) 17:167–78. 10.1016/S1074-7613(02)00367-9
33.
SuzukiHKundigTMFurlongerCWakehamATimmsEMatsuyamaTet al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. (1995) 268:1472–6. 10.1126/science.7770771
34.
BayerALYuAAdeegbeDMalekTR. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med. (2005) 201:769–77. 10.1084/jem.20041179
35.
SetoguchiRHoriSTakahashiTSakaguchiS. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. (2005) 201:723–35. 10.1084/jem.20041982
36.
YuAZhuLAltmanNHMalekTR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity. (2009) 30:204–17. 10.1016/j.immuni.2008.11.014
37.
ChinenTKannanAKLevineAGFanXKleinUZhengYet al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. (2016) 17:1322–33. 10.1038/ni.3540
38.
PandiyanPZhengLIshiharaSReedJLenardoMJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. (2007) 8:1353–62. 10.1038/ni1536
39.
TakahashiTTagamiTYamazakiSUedeTShimizuJSakaguchiNet al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. (2000) 192:303–10. 10.1084/jem.192.2.303
40.
FriedlineRHBrownDSNguyenHKornfeldHLeeJZhangYet al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. (2009) 206:421–34. 10.1084/jem.20081811
41.
WaterhousePPenningerJMTimmsEWakehamAShahinianALeeKPet al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. (1995) 270:985–8. 10.1126/science.270.5238.985
42.
TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. (1995) 3:541–7. 10.1016/1074-7613(95)90125-6
43.
WingKOnishiYPrieto-MartinPYamaguchiTMiyaraMFehervariZet al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. (2008) 322:271–5. 10.1126/science.1160062
44.
YokosukaTKobayashiWTakamatsuMSakata-SogawaKZengHHashimoto-TaneAet al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity. (2010) 33:326–39. 10.1016/j.immuni.2010.09.006
45.
SansomDMWalkerLS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. (2006) 212:131–48. 10.1111/j.0105-2896.2006.00419.x
46.
van der MerwePABodianDLDaenkeSLinsleyPDavisSJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. (1997) 185:393–403. 10.1084/jem.185.3.393
47.
QureshiOSZhengYNakamuraKAttridgeKManzottiCSchmidtEMet al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. (2011) 332:600–3. 10.1126/science.1202947
48.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev. Cancer. (2012) 12:252–64. 10.1038/nrc3239
49.
RibasAWolchokJD. Cancer immunotherapy using checkpoint blockade. Science. (2018) 359:1350–5. 10.1126/science.aar4060
50.
KretschmerKApostolouIHawigerDKhazaieKNussenzweigMCvon BoehmerH. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. (2005) 6:1219–27. 10.1038/ni1265
51.
ZhangXIziksonLLiuLWeinerHL. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol. (2001) 167:4245–53. 10.4049/jimmunol.167.8.4245
52.
ChenWJinWHardegenNLeiKJLiLMarinosNet al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. (2003) 198:1875–86. 10.1084/jem.20030152
53.
ZhengSGGrayJDOhtsukaKYamagiwaSHorwitzDA. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol. (2002) 169:4183–9. 10.4049/jimmunol.169.8.4183
54.
MarieJCLetterioJJGavinMRudenskyAY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. (2005) 201:1061–7. 10.1084/jem.20042276
55.
HuberSSchrammCLehrHAMannASchmittSBeckerCet al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol. (2004) 173:6526–31. 10.4049/jimmunol.173.11.6526
56.
SawantDVYanoHChikinaMZhangQLiaoMLiuCet al. Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. (2019) 20:724–35. 10.1038/s41590-019-0346-9
57.
DamoMJoshiNS. Treg cell IL-10 and IL-35 exhaust CD8(+) T cells in tumors. Nat Immunol. (2019) 20:674–5. 10.1038/s41590-019-0389-y
58.
KuhnRLohlerJRennickDRajewskyKMullerW. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. (1993) 75:263–74. 10.1016/0092-8674(93)80068-P
59.
MaynardCLHarringtonLEJanowskiKMOliverJRZindlCLRudenskyAYet al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol. (2007) 8:931–41. 10.1038/ni1504
60.
KamanakaMKimSTWanYYSutterwalaFSLara-TejeroMGalanJEet al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity. (2006) 25:941–52. 10.1016/j.immuni.2006.09.013
61.
RubtsovYPRasmussenJPChiEYFontenotJCastelliLYeXet al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. (2008) 28:546–58. 10.1016/j.immuni.2008.02.017
62.
ChaudhryASamsteinRMTreutingPLiangYPilsMCHeinrichJMet al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. (2011) 34:566–78. 10.1016/j.immuni.2011.03.018
63.
MuraiMTurovskayaOKimGMadanRKarpCLCheroutreHet al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. (2009) 10:1178–84. 10.1038/ni.1791
64.
MorGAldoPAlveroAB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. (2017) 17:469–82. 10.1038/nri.2017.64
65.
GnainskyYGranotIAldoPBarashAOrYMorGet al. Biopsy-induced inflammatory conditions improve endometrial receptivity: the mechanism of action. Reproduction. (2015) 149:75–85. 10.1530/REP-14-0395
66.
ZenclussenACHammerlingGJ. Cellular regulation of the uterine microenvironment that enables embryo implantation. Front Immunol. (2015) 6:321. 10.3389/fimmu.2015.00321
67.
DekelNGnainskyYGranotIRacicotKMorG. The role of inflammation for a successful implantation. Am J Reprod Immunol. (2014) 72:141–7. 10.1111/aji.12266
68.
SaitoSNakashimaAShimaTItoM. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. (2010) 63:601–10. 10.1111/j.1600-0897.2010.00852.x
69.
ErlebacherA. Mechanisms of T cell tolerance towards the allogeneic fetus. Nat Rev Immunol. (2013) 13:23–33. 10.1038/nri3361
70.
EdeyLFO'DeaKPHerbertBRHuaRWaddingtonSNMacIntyreDAet al. The local and systemic immune response to intrauterine LPS in the prepartum mouse. Biol Reprod. (2016) 95:125. 10.1095/biolreprod.116.143289
71.
LindstromTMBennettPR. The role of nuclear factor kappa B in human labour. Reproduction. (2005) 130:569–81. 10.1530/rep.1.00197
72.
MorGCardenasIAbrahamsVGullerS. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. (1221) (2011) 80–7. 10.1111/j.1749-6632.2010.05938.x
73.
GibreelABadawyAEl-RefaiWEl-AdawiN. Endometrial scratching to improve pregnancy rate in couples with unexplained subfertility: a randomized controlled trial. J Obstetr Gynaecol Res. (2013) 39:680–4. 10.1111/j.1447-0756.2012.02016.x
74.
GnainskyYGranotIAldoPBBarashAOrYSchechtmanEet al. Local injury of the endometrium induces an inflammatory response that promotes successful implantation. Fertil Steril. (2010) 94:2030–6. 10.1016/j.fertnstert.2010.02.022
75.
ZhouLLiRWangRHuangHXZhongK. Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates. Fertil Steril. (2008) 89:1166–76. 10.1016/j.fertnstert.2007.05.064
76.
GuvenSKartCUnsalMAYildirimOOdaciEYulugE. Endometrial injury may increase the clinical pregnancy rate in normoresponders undergoing long agonist protocol ICSI cycles with single embryo transfer. Eur J Obstetr Gynecol Reprod Biol. (2014) 173:58–62. 10.1016/j.ejogrb.2013.11.005
77.
MagedAMAl-InanyHSalamaKMSouidanIIAbo RagabHMElnasseryN. Endometrial scratch injury induces higher pregnancy rate for women with unexplained infertility undergoing IUI with ovarian stimulation: a randomized controlled trial. Reprod Sci. (2016) 23:239–43. 10.1177/1933719115602776
78.
AchacheHRevelA. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Update. (2006) 12:731–46. 10.1093/humupd/dml004
79.
LiuSDiaoLHuangCLiYZengYKwak-KimJYH. The role of decidual immune cells on human pregnancy. J Reprod Immunol. (2017) 124:44–53. 10.1016/j.jri.2017.10.045
80.
PlaksVBirnbergTBerkutzkiTSelaSBenYasharAKalchenkoVet al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest. (2008) 118:3954–65. 10.1172/JCI36682
81.
AcarNUstunelIDemirR. Uterine natural killer (uNK) cells and their missions during pregnancy: a review. Acta histochemica. (2011) 113:82–91. 10.1016/j.acthis.2009.12.001
82.
HeitmannRJWeitzelRPFengYSegarsJHTisdaleJFWolffEF. Maternal T regulatory cell depletion impairs embryo implantation which can be corrected with adoptive t regulatory cell transfer. Reprod Sci. (2017) 24:1014–24. 10.1177/1933719116675054
83.
JasperMJTremellenKPRobertsonSA. Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in endometrial tissue. Mol Hum Reprod. (2006) 12:301–8. 10.1093/molehr/gal032
84.
ZhouJWangZZhaoXWangJSunHHuY. An increase of Treg cells in the peripheral blood is associated with a better in vitro fertilization treatment outcome. Am J Reprod Immunol. (2012) 68:100–6. 10.1111/j.1600-0897.2012.01153.x
85.
LuYZhangFZhangYZengBHuLLiaoA. Quantitative reduction of peripheral CD4+ CD25+ FOXP3+ regulatory T cells in reproductive failure after artificial insemination by donor sperm. Am J Reprod Immunol. (2013) 69:188–93. 10.1111/aji.12041
86.
JollerNLozanoEBurkettPRPatelBXiaoSZhuCet al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. (2014) 40:569–81. 10.1016/j.immuni.2014.02.012
87.
RobertsonSAPrinsJRSharkeyDJMoldenhauerLM. Seminal fluid and the generation of regulatory T cells for embryo implantation. Am J Reprod Immunol. (2013) 69:315–30. 10.1111/aji.12107
88.
GuerinLRMoldenhauerLMPrinsJRBromfieldJJHayballJDRobertsonSA. Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment. Biol Reprod. (2011) 85:397–408. 10.1095/biolreprod.110.088591
89.
RobertsonSAGuerinLRBromfieldJJBransonKMAhlstromACCareAS. Seminal fluid drives expansion of the CD4+CD25+ T regulatory cell pool and induces tolerance to paternal alloantigens in mice. Biol Reprod. (2009) 80:1036–45. 10.1095/biolreprod.108.074658
90.
MoldenhauerLMDienerKRThringDMBrownMPHayballJDRobertsonSA. Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy. J Immunol. (2009) 182:8080–93. 10.4049/jimmunol.0804018
91.
ClarkDAFernandesJBanwattD. Prevention of spontaneous abortion in the CBA x DBA/2 mouse model by intravaginal TGF-beta and local recruitment of CD4+8+ FOXP3+ cells. Am J Reprod Immunol. (2008) 59:525–34. 10.1111/j.1600-0897.2008.00582.x
92.
BaratelliFLinYZhuLYangSCHeuze-Vourc'hNZengGet al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. (2005) 175:1483–90. 10.4049/jimmunol.175.3.1483
93.
KahnDABaltimoreD. Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci USA. (2010) 107:9299–304. 10.1073/pnas.1003909107
94.
AluvihareVRKallikourdisMBetzAG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. (2004) 5:266–71. 10.1038/ni1037
95.
ZhaoJXZengYYLiuY. Fetal alloantigen is responsible for the expansion of the CD4(+)CD25(+) regulatory T cell pool during pregnancy. J Reprod Immunol. (2007) 75:71–81. 10.1016/j.jri.2007.06.052
96.
SamsteinRMJosefowiczSZArveyATreutingPMRudenskyAY. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell. (2012) 150:29–38. 10.1016/j.cell.2012.05.031
97.
LathamKAZamoraADroughtHSubramanianSMatejukAOffnerHet al. Estradiol treatment redirects the isotype of the autoantibody response and prevents the development of autoimmune arthritis. J Immunol. (2003) 171:5820–7. 10.4049/jimmunol.171.11.5820
98.
GourdyPBourgeoisEALevescotAPhamLRiantEAhuiMLet al. Estrogen therapy delays autoimmune diabetes and promotes the protective efficiency of natural killer T-cell activation in female nonobese diabetic Mice. Endocrinology. (2016) 157:258–67. 10.1210/en.2015-1313
99.
BeboBFJrFyfe-JohnsonAAdlardKBeamAGVandenbarkAAOffnerH. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol. (2001) 166:2080–9. 10.4049/jimmunol.166.3.2080
100.
LiaoZHHuangTXiaoJWGuRCOuyangJWuGet al. Estrogen signaling effects on muscle-specific immune responses through controlling the recruitment and function of macrophages and T cells. Skelet Muscle. (2019) 9:20. 10.1186/s13395-019-0205-2
101.
SeifertHABenedekGNguyenHKentGVandenbarkAAOffnerH. Estrogen protects both sexes against EAE by promoting common regulatory cell subtypes independent of endogenous estrogen. Metab Brain Dis. (2017) 32:1747–1754. 10.1007/s11011-017-0063-8
102.
HaghmoradDAminiAAMahmoudiMBRastinMHosseiniMMahmoudiM. Pregnancy level of estrogen attenuates experimental autoimmune encephalomyelitis in both ovariectomized and pregnant C57BL/6 mice through expansion of Treg and Th2 cells. J Neuroimmunol. (2014) 277:85–95. 10.1016/j.jneuroim.2014.10.004
103.
ArruvitoLSanzMBanhamAHFainboimL. Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol. (2007) 178:2572–8. 10.4049/jimmunol.178.4.2572
104.
PolanczykMZamoraASubramanianSMatejukAHessDLBlankenhornEPet al. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol. (2003) 163:1599–605. 10.1016/S0002-9440(10)63516-X
105.
PrietoGARosensteinY. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology. (2006) 118:58–65. 10.1111/j.1365-2567.2006.02339.x
106.
PolanczykMJCarsonBDSubramanianSAfentoulisMVandenbarkAAZieglerSFet al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol. (2004) 173:2227–30. 10.4049/jimmunol.173.4.2227
107.
TaiPWangJJinHSongXYanJKangYet al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. (2008) 214:456–64. 10.1002/jcp.21221
108.
MaoGWangJKangYTaiPWenJZouQet al. Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. Endocrinology. (2010) 151:5477–88. 10.1210/en.2010-0426
109.
HierwegerAMEnglerJBFrieseMAReichardtHMLydonJDeMayoFet al. Progesterone modulates the T-cell response via glucocorticoid receptor-dependent pathways. Am J Reprod Immunol. (2019) 81:e13084. 10.1111/aji.13084
110.
EnglerJBKursaweNSolanoMEPatasKWehrmannSHeckmannNet al. Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. Proc Natl Acad Sci USA. (2017) 114:E181–90. 10.1073/pnas.1617115114
111.
Rocamora-ReverteLReichardtHMVillungerAWiegersG. T-cell autonomous death induced by regeneration of inert glucocorticoid metabolites. Cell Death Dis. (2017) 8:e2948. 10.1038/cddis.2017.344
112.
LeeJHUlrichBChoJParkJKimCH. Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol. (2011) 187:1778–87. 10.4049/jimmunol.1003919
113.
EnningaEAHoltanSGCreedonDJDroncaRSNevalaWKOgnjanovicSet al. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc. (2014) 89:520–35. 10.1016/j.mayocp.2014.01.006
114.
KhilLYJunHSKwonHYooJKKimSNotkinsALet al. Human chorionic gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice. Diabetologia. (2007) 50:2147–55. 10.1007/s00125-007-0769-y
115.
SchumacherAHeinzeKWitteJPoloskiELinzkeNWoidackiKet al. Human chorionic gonadotropin as a central regulator of pregnancy immune tolerance. J Immunol. (2013) 190:2650–8. 10.4049/jimmunol.1202698
116.
SchumacherABrachwitzNSohrSEngelandKLangwischSDolaptchievaMet al. Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. J Immunol. (2009) 182:5488–97. 10.4049/jimmunol.0803177
117.
PoloskiEOettelAEhrentrautSLuleyLCostaSDZenclussenACet al. JEG-3 trophoblast cells producing human chorionic gonadotropin promote conversion of human CD4+FOXP3- T cells into CD4+FOXP3+ regulatory T cells and foster T cell suppressive activity. Biol Reprod. (2016) 94:106. 10.1095/biolreprod.115.135541
118.
LutzMBSchulerG. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?Trends Immunol. (2002) 23:445–9. 10.1016/S1471-4906(02)02281-0
119.
DiaoLHLiGGZhuYCTuWWHuangCYLianRCet al. Human chorionic gonadotropin potentially affects pregnancy outcome in women with recurrent implantation failure by regulating the homing preference of regulatory T cells. Am J Reprod Immunol. (2017) 77:e12618. 10.1111/aji.12618
120.
Sindram-TrujilloAPScherjonSAvanHulst-van Miert PPKanhaiHHRoelenDLClaasFH. Comparison of decidual leukocytes following spontaneous vaginal delivery and elective cesarean section in uncomplicated human term pregnancy. J Reprod Immunol. (2004) 62:125–37. 10.1016/j.jri.2003.11.007
121.
ShahNMEdeyLFImamiNJohnsonMR. Human labour is associated with altered regulatory T cell function and maternal immune activation. Clin Exp Immunol. (2020) 199:182–200. 10.1111/cei.13384
122.
KisielewiczASchaierMSchmittEHugFHaenschGMMeuerSet al. A distinct subset of HLA-DR+-regulatory T cells is involved in the induction of preterm labor during pregnancy and in the induction of organ rejection after transplantation. Clin Immunol. (2010) 137:209–20. 10.1016/j.clim.2010.07.008
123.
SchoberLRadnaiDSchmittEMahnkeKSohnCSteinbornA. Term and preterm labor: decreased suppressive activity and changes in composition of the regulatory T-cell pool. Immunol Cell Biol. (2012) 90:935–44. 10.1038/icb.2012.33
124.
RosenblumMDWaySSAbbasAK. Regulatory T cell memory. Nat Rev Immunol. (2016) 16:90–101. 10.1038/nri.2015.1
125.
RoweJHErteltJMXinLWaySS. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature. (2012) 490:102–6. 10.1038/nature11462
126.
KinderJMJiangTTClarkDRChaturvediVXinLErteltJMet al. Pregnancy-induced maternal regulatory T cells, bona fide memory or maintenance by antigenic reminder from fetal cell microchimerism?Chimerism. (2014) 5:16–9. 10.4161/chim.28241
127.
RaiRReganL. Recurrent miscarriage. Lancet. (2006) 368:601–11. 10.1016/S0140-6736(06)69204-0
128.
BranchDWGibsonMSilverRM. Clinical practice. recurrent miscarriage. N Engl J Med. (2010) 363:1740–7. 10.1056/NEJMcp1005330
129.
StirratGM. Recurrent miscarriage. II: Clinical associations, causes, and management. Lancet (1990) 336:728–33. 10.1016/0140-6736(90)92215-4
130.
ZhangCDengXZhangXPanZZhaoWZhangYet al. Association between Serum TNF-alpha levels and recurrent spontaneous miscarriage: a meta-analysis. Am J Reprod Immunol. (2016) 75:86–93. 10.1111/aji.12447
131.
Kwak-KimJBaoSLeeSKKimJWGilman-SachsA. Immunological modes of pregnancy loss: inflammation, immune effectors, and stress. Am J Reprod Immunol. (2014) 72:129–40. 10.1111/aji.12234
132.
LeeSKKimJYHurSEKimCJNaBJLeeMet al. An imbalance in interleukin-17-producing T and Foxp3(+) regulatory T cells in women with idiopathic recurrent pregnancy loss. Hum Reprod. (2011) 26:2964–71. 10.1093/humrep/der301
133.
Kwak-KimJYChung-BangHSNgSCNtrivalasEIMangubatCPBeamanKDet al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod. (2003) 18:767–73. 10.1093/humrep/deg156
134.
WangWJHaoCFQuQLWangXQiuLHLinQD. The deregulation of regulatory T cells on interleukin-17-producing T helper cells in patients with unexplained early recurrent miscarriage. Hum Reprod. (2010) 25:2591–6. 10.1093/humrep/deq198
135.
WuLLiJXuHLXuBTongXHKwak-KimJet al. IL-7/IL-7R signaling pathway might play a role in recurrent pregnancy losses by increasing inflammatory Th17 cells and decreasing Treg cells. Am J Reprod Immunol. (2016) 76:454–64. 10.1111/aji.12588
136.
WangWJLiuFJXinLHaoCFBaoHCQuQLet al. Adoptive transfer of pregnancy-induced CD4+CD25+ regulatory T cells reverses the increase in abortion rate caused by interleukin 17 in the CBA/JxBALB/c mouse model. Hum Reprod. (2014) 29:946–52. 10.1093/humrep/deu014
137.
ZenclussenACGerlofKZenclussenMLSollwedelABertojaAZRitterTet al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol. (2005) 166:811–22. 10.1016/S0002-9440(10)62302-4
138.
JinLPChenQYZhangTGuoPFLiDJ. The CD4+CD25 bright regulatory T cells and CTLA-4 expression in peripheral and decidual lymphocytes are down-regulated in human miscarriage. Clin Immunol. (2009) 133:402–10. 10.1016/j.clim.2009.08.009
139.
MeiSTanJChenHChenYZhangJ. Changes of CD4+CD25high regulatory T cells and FOXP3 expression in unexplained recurrent spontaneous abortion patients. Fertil Steril. (2010) 94:2244–7. 10.1016/j.fertnstert.2009.11.020
140.
WingerEEReedJL. Low circulating CD4(+) CD25(+) Foxp3(+) T regulatory cell levels predict miscarriage risk in newly pregnant women with a history of failure. Am J Reprod Immunol. (2011) 66:320–8. 10.1111/j.1600-0897.2011.00992.x
141.
BaoSHWangXPDe LinQWangWJYinGJQiuLH. Decidual CD4+CD25+CD127dim/-regulatory T cells in patients with unexplained recurrent spontaneous miscarriage. Euro J Obstetr Gynecol Reprod Biol. (2011) 155:94–8. 10.1016/j.ejogrb.2010.11.007
142.
ZhuLChenHLiuMYuanYWangZChenYet al. Treg/Th17 cell imbalance and IL-6 profile in patients with unexplained recurrent spontaneous abortion. Reprod Sci. (2017) 24:882–90J.
143.
QianJZhangNLinJWangCPanXChenLet al. Distinct pattern of Th17/Treg cells in pregnant women with a history of unexplained recurrent spontaneous abortion. Biosci Trends. (2018) 12:157–67. 10.5582/bst.2018.01012
144.
GiudiceLCKaoLC. Endometriosis. Lancet. (2004) 364:1789–99. 10.1016/S0140-6736(04)17403-5
145.
BulunSE. Endometriosis. N Engl J Med. (2009) 360:268–79. 10.1056/NEJMra0804690
146.
ChapronCMarcellinLBorgheseBSantulliP. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. (2019) 15:666–82. 10.1038/s41574-019-0245-z
147.
D'HoogheTMDebrockS. Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Hum Reprod Update. (2002) 8:84–8. 10.1093/humupd/8.1.84
148.
HalmeJHammondMGHulkaJFRajSGTalbertLM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstetri Gynecol. (1984) 64:151–4.
149.
OlovssonM. Immunological aspects of endometriosis: an update. Am J Reprod Immunol. (2011) 66(Suppl. 1):101–4. 10.1111/j.1600-0897.2011.01045.x
150.
SciezynskaAKomorowskiMSoszynskaMMalejczykJ. NK cells as potential targets for immunotherapy in endometriosis. J Clin Med. (2019) 8:1468. 10.3390/jcm8091468
151.
ZhangTDe CarolisCGManCWWangCC. The link between immunity, autoimmunity and endometriosis: a literature update. Autoimmunity Rev. (2018) 17:945–55. 10.1016/j.autrev.2018.03.017
152.
BacciMCapobiancoAMonnoACottoneLDi PuppoFCamisaBet al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol. (2009) 175:547–56. 10.2353/ajpath.2009.081011
153.
ZhouWJYangHLShaoJMeiJChangKKZhuRet al. Anti-inflammatory cytokines in endometriosis. Cell Mol Life Sci. (2019) 76:2111–32. 10.1007/s00018-019-03056-x
154.
HoHNChaoKHChenHFWuMYYangYSLeeTY. Peritoneal natural killer cytotoxicity and CD25+ CD3+ lymphocyte subpopulation are decreased in women with stage III-IV endometriosis. Hum Reprod. (1995) 10:2671–5. 10.1093/oxfordjournals.humrep.a135765
155.
TakamuraMKogaKIzumiGHirataTHaradaMHirotaYet al. Simultaneous detection and evaluation of four subsets of CD4+ T lymphocyte in lesions and peripheral blood in endometriosis. Am J Reprod Immunol. (2015) 74:480–6. 10.1111/aji.12426
156.
BastaPMajkaMJozwickiWLukaszewskaEKnafelAGrabiecMet al. The frequency of CD25+CD4+ and FOXP3+ regulatory T cells in ectopic endometrium and ectopic decidua. Reprod Biol Endocrinol. (2010) 8:116. 10.1186/1477-7827-8-116
157.
PodgaecSRizzoLVFernandesLFBaracatECAbraoMS. CD4(+) CD25(high) Foxp3(+) cells increased in the peritoneal fluid of patients with endometriosis. Am J Reprod Immunol. (2012) 68:301–8. 10.1111/j.1600-0897.2012.01173.x
158.
Olkowska-TruchanowiczJBocianKMaksymRBBialoszewskaAWlodarczykDBaranowskiWet al. CD4(+) CD25(+) FOXP3(+) regulatory T cells in peripheral blood and peritoneal fluid of patients with endometriosis. Hum Reprod. (2013) 28:119–24. 10.1093/humrep/des346
159.
GogaczMWinklerIBojarska-JunakATabarkiewiczJSemczukARechbergerTet al. T regulatory lymphocytes in patients with endometriosis. Mol Med Rep. (2014) 10:1072–6. 10.3892/mmr.2014.2294
160.
TanakaYMoriTItoFKoshibaATakaokaOKataokaHet al. Exacerbation of endometriosis due to regulatory T-cell dysfunction. J Clin Endocrinol Metab. (2017) 102:3206–17. 10.1210/jc.2017-00052
161.
HanadaTTsujiSNakayamaMWakinoueSKasaharaKKimuraFet al. Suppressive regulatory T cells and latent transforming growth factor-beta-expressing macrophages are altered in the peritoneal fluid of patients with endometriosis. Reprod Biol Endocrinol. (2018) 16:9. 10.1186/s12958-018-0325-2
162.
KhanKNYamamotoKFujishitaAMutoHKoshibaAKuroboshiHet al. Differential levels of regulatory T-cells and T-helper-17 cells in women with early and advanced endometriosis. J Clin Endocrinol Metab. (2019) 104:4715–29. 10.1210/jc.2019-00350
163.
BraundmeierAJacksonKHastingsJKoehlerJNowakRFazleabasA. Induction of endometriosis alters the peripheral and endometrial regulatory T cell population in the non-human primate. Hum Reprod. (2012) 27:1712–22. 10.1093/humrep/des083
164.
ZhangXHeiPDengLLinJ. Interleukin-10 gene promoter polymorphisms and their protein production in peritoneal fluid in patients with endometriosis. Mol Hum Reprod. (2007) 13:135–40. 10.1093/molehr/gal106
165.
SikoraJSmycz-KubanskaMMielczarek-PalaczABednarekIKondera-AnaszZ. The involvement of multifunctional TGF-beta and related cytokines in pathogenesis of endometriosis. Immunol Lett. (2018) 201:31–7. 10.1016/j.imlet.2018.10.011
166.
Gueuvoghlanian-SilvaBYBellelisPBarbeiroDFHernandesCPodgaecS. Treg and NK cells related cytokines are associated with deep rectosigmoid endometriosis and clinical symptoms related to the disease. J Reprod Immunol. (2018) 126:32–8. 10.1016/j.jri.2018.02.003
167.
MolBWJRobertsCTThangaratinamSMageeLAde GrootCJMHofmeyrGJ. Pre-eclampsia. Lancet. (2016) 387:999–1011. 10.1016/S0140-6736(15)00070-7
168.
WilliamsPJBroughton PipkinF. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. (2011) 25:405–17. 10.1016/j.bpobgyn.2011.02.007
169.
PoweCELevineRJKarumanchiSA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. (2011) 123:2856–69. 10.1161/CIRCULATIONAHA.109.853127
170.
LyallFRobsonSCBulmerJN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. Hypertension. (2013) 62:1046–54. 10.1161/HYPERTENSIONAHA.113.01892
171.
LockwoodCJYenCFBasarMKayisliUAMartelMBuhimschiIet al. Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. Am J Pathol. (2008) 172:1571–9. 10.2353/ajpath.2008.070629
172.
Gonzalez-ComadranMUrresta AvilaJSaavedra TasconAJimenezRSolaIBrassescoMet al. The impact of donor insemination on the risk of preeclampsia: a systematic review and meta-analysis. Eur J Obstetr Gynecol Reprod Biol. (2014) 182:160–6. 10.1016/j.ejogrb.2014.09.022
173.
SaftlasAFRubensteinLPraterKHarlandKKFieldETricheEW. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol. (2014) 102:104–10. 10.1016/j.jri.2013.07.006
174.
EinarssonJISangi-HaghpeykarHGardnerMO. Sperm exposure and development of preeclampsia. Am J Obstetr Gynecol. (2003) 188:1241–3. 10.1067/mob.2003.401
175.
Santner-NananBPeekMJKhanamRRichartsLZhuEFazekas de St GrothBet al. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol. (2009) 183:7023–30. 10.4049/jimmunol.0901154
176.
FigueiredoASSchumacherA. The T helper type 17/regulatory T cell paradigm in pregnancy. Immunology. (2016) 148:13–21. 10.1111/imm.12595
177.
HosseiniADolatiSHashemiVAbdollahpour-AlitappehMYousefiM. Regulatory T and T helper 17 cells: their roles in preeclampsia. J Cell Physiol. (2018) 233:6561–6573. 10.1002/jcp.26604
178.
Eghbal-FardSYousefiMHeydarlouHAhmadiMTaghaviSMovasaghpourAet al. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. J Cell Physiol. (2019) 234:5106–16. 10.1002/jcp.27315
179.
MolvarecACzegleISzijartoJRigoJJr. Increased circulating interleukin-17 levels in preeclampsia. J Reprod Immunol. (2015) 112:53–7. 10.1016/j.jri.2015.05.007
180.
Darmochwal-KolarzDKludka-SternikMTabarkiewiczJKolarzBRolinskiJLeszczynska-GorzelakBet al. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol. (2012) 93:75–81. 10.1016/j.jri.2012.01.006
181.
RobertsonSAGreenESCareASMoldenhauerLMPrinsJRHullMLet al. Therapeutic potential of regulatory T cells in preeclampsia-opportunities and challenges. Front Immunol. (2019) 10:478. 10.3389/fimmu.2019.00478
182.
TsudaSZhangXHamanaHShimaTUshijimaATsudaKet al. Clonally expanded decidual effector regulatory T cells increase in late gestation of normal pregnancy, but not in preeclampsia, in humans. Front Immunol. (2018) 9:1934. 10.3389/fimmu.2018.01934
183.
HsuPSantner-NananBDahlstromJEFadiaMChandraAPeekMet al. Altered decidual DC-SIGN+ antigen-presenting cells and impaired regulatory T-cell induction in preeclampsia. Am J Pathol. (2012) 181:2149–60. 10.1016/j.ajpath.2012.08.032
184.
SharabiATsokosMGDingYMalekTRKlatzmannDTsokosGC. Regulatory T cells in the treatment of disease. Nat Rev Drug Discover. (2018) 17:823–44. 10.1038/nrd.2018.148
185.
YinYHanXShiQZhaoYHeY. Adoptive transfer of CD4+CD25+ regulatory T cells for prevention and treatment of spontaneous abortion. Eur J Obstetr Gynecol Reprod Biol. (2012) 161:177–81. 10.1016/j.ejogrb.2011.12.023
186.
LiuMZhenXSongHChenJSunXLiXet al. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage. Reprod Biol Endocrinol. (2017) 15:95. 10.1186/s12958-017-0315-9
187.
JafarzadehSAhmadiMDolatiSAghebati-MalekiLEghbal-FardSKamraniAet al. Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. J Cell Biochem. (2019) 120:5424–5434. 10.1002/jcb.27821
188.
MuyayaloKPLiZHMorGLiaoAH. Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion. Am J Reprod Immunol. (2018) 80:e13018. 10.1111/aji.13018
189.
WuLLuoLHZhangYXLiQXuBZhouGXet al. Alteration of Th17 and Treg cells in patients with unexplained recurrent spontaneous abortion before and after lymphocyte immunization therapy. Reprod Biol Endocrinol. (2014) 12:74. 10.1186/1477-7827-12-74
190.
YangHQiuLDiWZhaoAChenGHuKet al. Proportional change of CD4+CD25+ regulatory T cells after lymphocyte therapy in unexplained recurrent spontaneous abortion patients. Fertil Steril. (2009) 92:301–5. 10.1016/j.fertnstert.2008.04.068
191.
AhmadiMAghdamSANouriMBabalooZFarzadiLGhasemzadehAet al. Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: non randomized, open-label clinical trial. Immunology Lett. (2017) 192:12–9. 10.1016/j.imlet.2017.10.003
192.
KimDJLeeSKKimJYNaBJHurSELeeMet al. Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss. Am J Reprod Immunol. (2014) 71:441–50. 10.1111/aji.12208
193.
RoysterGDHarrisJCNelsonACastroYWeitzelRPTisdaleJet al. Rapamycin corrects T regulatory cell depletion and improves embryo implantation and live birth rates in a murine model. Reprod Sci. (2019) 26:1545–56. 10.1177/1933719119828110
194.
AhmadiMAbdolmohamadi-VahidSGhaebiMDolatiSAbbaspour-AghdamSDanaiiSet al. Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: a double-blind, phase II randomized clinical trial. Int Immunopharmacol. (2019) 74:105730. 10.1016/j.intimp.2019.105730
Summary
Keywords
regulatory T cells, pregnancy, steroidogenesis, endometriosis, primary unexplained infertility, recurrent spontaneous abortion, preeclampsia
Citation
Huang N, Chi H and Qiao J (2020) Role of Regulatory T Cells in Regulating Fetal-Maternal Immune Tolerance in Healthy Pregnancies and Reproductive Diseases. Front. Immunol. 11:1023. doi: 10.3389/fimmu.2020.01023
Received
12 January 2020
Accepted
28 April 2020
Published
26 June 2020
Volume
11 - 2020
Edited by
Sarah Anne Robertson, University of Adelaide, Australia
Reviewed by
Lianjun Zhang, Suzhou Institute of Systems Medicine (ISM), China; Alexander Steinkasserer, University Hospital Erlangen, Germany
Updates
Copyright
© 2020 Huang, Chi and Qiao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongbin Chi chihb@163.comJie Qiao jie.qiao@263.net
This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.